OP- 10 - NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: A COMPARATIVE ANALYSIS BETWEEN THE SPANISH AND LATINDILI NETWORKS
No Background: Non-steroidal anti-inflammatory drugs (NSAIDs) represent a frequent cause of drug-induced liver injury (DILI). Aim: To compare demographics, clinical characteristics and outcomes of NSAIDs-induced liver injury between the LATINDILI and the Spanish DILI Registries. We analyzed 49 out of 468 LATINDILI cases (10,5%) and 82 out of 1254 Spanish DILI Registry cases (14%) induced by NSAIDs. In Spanish DILI cases, ibuprofen (33%), diclofenac (18%) and nimesulide (11%), were the most frequent culprit drugs, while diclofenac (33%), nimesulide (29%), ibuprofen (18%) and etoricoxib (10%) were the most common offending agents in LATINDILI cases. Surprisingly, etoricoxib was far more frequent in LATINDILI (10%) than in the Spanish DILI Registry (1.2%). Females predominated in Latin American cases (73%) compared to Spanish cases (47%) (p=0.011). Also, there was a trend towards a higher hospitalization rate in Spanish cases (63%) compared to LATINDILI cases (43%). (p=0.057). Notably, Hy's law showed to have drug-specific predictive value, with ibuprofen, nimesulide and etoricoxib associated with fatal outcomes, whereas DILI due to other AINEs did not have a worse outcome. We separately analyzed cases due to the most frequent culprits in each registry (ibuprofen and diclofenac). Notably, one patient died and one patient underwent liver transplantation linked to ibuprofen in the Spanish DILI Registry, while no death nor liver transplants were recorded in the LATINDILI due to ibuprofen. Likewise, no fatal outcome related to diclofenac were observed in these registries Differences in the incidence of DILI due to NSAIDs may reflect different prescribing patterns and public health policies in distinct countries. Ibuprofen can cause serious liver damage, and different doses in the OTC market and genetic factors may explain the differences in frequencies between registries. Hy's law prognostic performance varies between NSAIDs and is highest for nimesulide and ibuprofen. Etoricoxib DILI needs further investigation.
Authors
- Hao Niu (ORCID: https://orcid.org/0000-0002-3030-3972)
- Nelia Hernández (ORCID: https://orcid.org/0000-0001-6816-3699)
- M. González
- Hugo Tanno
- Daniela Chiodi
- Fernando Bessone (ORCID: https://orcid.org/0000-0002-8569-8123)
- Raymundo Paraná (ORCID: https://orcid.org/0000-0002-4019-4597)
- Manuel Mendizábal (ORCID: https://orcid.org/0000-0002-7026-9908)
- Federico Tanno
- Ezequiel Ridruejo (ORCID: https://orcid.org/0000-0002-3321-0683)
- Gisela Gualano
- Antonella Cordone
- Inmaculada Medina Cáliz
- María Isabel Schinoni (ORCID: https://orcid.org/0000-0001-9037-8127)
- Javier Brahm
- María Virginia Reggiardo (ORCID: https://orcid.org/0000-0003-3990-5790)
- E Fassio (ORCID: https://orcid.org/0000-0002-9092-464X)
- Daiana Arnedillo
- Gabriel Rifrani
- I. A. Alvarez
- Robert Andrade
Institutions
- Universidade Federal da Bahia (BR)
- Universidad de Los Andes, Chile (CL)
- National University of Santiago del Estero (AR)
- Hospital Universitario Austral (AR)
- Hospital Provincial de Rosario (AR)
- Instituto de Gastroenterología (CU)
- Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (AR)
- Hospital Posadas (AR)
- Hospital de Clínicas (UY)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
Publication Details
- Journal
- Annals of Hepatology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.aohep.2024.101608
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.40